SML0223
唑来膦酸 一水合物
≥98% (HPLC), FPP synthase inhibitor, powder
别名:
P,P′-[1-羟基-2-（1H-咪唑-1-基）亚乙基]双膦酸 一水合物, [1-羟基-2-（1H-咪唑-1-基）乙烷-1,1-二基]双（膦酸） 一水合物, 唑来膦酸 一水合物
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H10N2O7P2·H2O
化学文摘社编号:
分子量:
290.10
UNSPSC Code:
12352204
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
唑来膦酸 一水合物, ≥98% (HPLC)
SMILES string
O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
InChI key
FUXFIVRTGHOMSO-UHFFFAOYSA-N
InChI
1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
assay
≥98% (HPLC)
form
powder
storage condition
desiccated, protect from light
color
white to beige
solubility
H2O: ≥2 mg/mL
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
相关类别
Application
唑来膦酸一水合物用作：
- 作为抑制剂，抑制胶质母细胞瘤、乳腺癌肿瘤细胞 和前列腺癌细胞系LAPC4的增殖
- 与 D,L-丙交酯75：乙交酯25（PLGA）形成缀合物，分析其在股骨远端的骨形成功能
- 作为胶质母细胞瘤细胞中法尼基二磷酸合酶的抑制剂
Biochem/physiol Actions
唑来膦酸（唑来膦酸盐）是一种双膦酸盐骨吸收抑制剂，是基焦磷酸（FPP）合成酶的抑制剂，其会导致破骨细胞活性的下游抑制并减少骨吸收和转换。它已被用于治疗绝经后的骨质疏松症，佩吉特病、高钙血症，并结合癌症化疗以治疗已经扩散到骨骼的癌症引起的骨损伤。
唑来膦酸（唑来膦酸盐）是一种骨吸收抑制剂，是基焦磷酸合成酶的抑制剂
Preparation Note
本品在溶液中极其不稳定，复溶后应尽快使用。如果一定要保存溶液，最多可在2-8ºC下存放24小时。
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness
Kim HY, et al.
Experimental & Molecular Medicine, 50(10), 137-137 (2018)
Wei Lei et al.
Scientific reports, 10(1), 7004-7004 (2020-04-26)
The most challenging issue for breast cancer (BC) patients is metastasis to other organs because current therapies do not prevent or eliminate metastatic BC. Here, we show that SM-164, a small molecule inhibitor, which degrades inhibitor of apoptosis proteins (IAPs)
David John Garnett
Journal of cancer research and clinical oncology, 142(3), 611-618 (2015-11-18)
Mevalonate pathway inhibitors are potentially useful chemotherapeutic agents showing growth inhibition and pro-apoptotic effects in cancer cells. The effects of statins and bisphosphonates on cancer growth are attributed to a reduction in protein isoprenylation. Post-translational modification and activation of GTPase
Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells
Jiang P, et al.
Testing, 7(36), 57932-57932 (2016)
Xu Li et al.
International journal of pharmaceutics, 526(1-2), 69-76 (2017-04-30)
Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持